STOCK TITAN

Gamida Cell to Report Second Quarter 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Gamida Cell Ltd. will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. A conference call and live webcast will be held at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions. The webcast can be accessed on the Gamida Cell website.
Positive
  • None.
Negative
  • None.

Conference Call and Webcast Scheduled for Monday, August 14th at 8:30 am Eastern Time

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023.

Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions.

To access the conference call by phone, please register here and be advised to do so at least 10 minutes prior to joining. A live webcast of the conference call can be accessed by computer in the “Investors & Media” section of the Gamida Cell website at www.gamida-cell.com. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Gamida Cell

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge®, an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an NK cell therapy candidate being investigated for the treatment of hematologic malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram.

Omisirge® is a registered trademark of Gamida Cell Inc. © 2023 Gamida Cell Inc. All Rights Reserved.

Investor Contacts:

Chuck Padala

LifeSci Advisors

chuck@lifesciadvisors.com

1-646-627-8390

Media Contact:

Dan Boyle

Orangefiery

media@orangefiery.com

1-818-209-1692

Source: Gamida Cell Ltd.

FAQ

When will Gamida Cell release its financial results for the second quarter?

Gamida Cell will release its financial results for the second quarter on Monday, August 14, 2023.

What time will the conference call and webcast be held?

The conference call and live webcast will be held at 8:30 am Eastern Time.

Where can I access the webcast?

The webcast can be accessed on the Gamida Cell website in the 'Investors & Media' section.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available approximately two hours after the event and will be accessible for approximately 30 days.

Gamida Cell Ltd.

NASDAQ:GMDA

GMDA Rankings

GMDA Latest News

GMDA Stock Data

4.34M
120.38M
11.58%
26.49%
7.53%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Jerusalem

About GMDA

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.